Emergency Department Visits Before Cancer Diagnosis Among Women at Mayo Clinic
CONCLUSION: Patient characteristics identified in this study offer opportunities to provide cancer risk assessment and health navigation, particularly among individuals with comorbidities and limited health care access.PMID:38596167 | PMC:PMC11002794 | DOI:10.1016/j.mayocpiqo.2024.03.002 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Sally K Stauder Shalmali R Borkar Amy E Glasgow Tage L Runkle Mark E Sherman Aaron C Spaulding Michael M Mohseni Christopher C DeStephano Source Type: research
Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC
CONCLUSIONS: The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.PMID:38596201 | PMC:PMC11001639 | DOI:10.1016/j.jtocrr.2024.100659 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Tsuyoshi Hirata Yuji Uehara Taiki Hakozaki Takayuki Kobayashi Yuto Terashima Kageaki Watanabe Makiko Yomota Yukio Hosomi Source Type: research
Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer
CONCLUSION: First-line ICIs plus chemotherapy should be applied in clinical practice. If patients did not use ICIs plus chemotherapy in first-line therapy, the use of ICIs in the second line or subsequent lines of treatment could prolong PFS2.PMID:38598001 | DOI:10.1007/s12094-024-03471-y (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Song Mi Yunxin Yang Xin Liu Shaotong Tang Ning Liang Jinyue Sun Chao Liu Qidong Ren Jihong Lu Pingping Hu Jiandong Zhang Source Type: research
Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography
CONCLUSION: Our nomogram based on preoperative 18F-FDG PET/CT radiological features and SUVmax effectively predicts STAS status in clinical-stage IA NSCLC. Furthermore, our study highlights that metabolic parameters and CT variables associated with STAS differ between solid and part-solid nodular NSCLC.PMID:38598007 | PMC:PMC11006761 | DOI:10.1007/s00432-024-05674-w (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Yun Wang Deng Lyu Chao Cheng Taohu Zhou Wenting Tu Yi Xiao Changjing Zuo Li Fan Shiyuan Liu Source Type: research
Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data
CONCLUSION: A high number of concurrent medications was associated with poor clinical outcomes.PMID:38600328 | PMC:PMC11006739 | DOI:10.1007/s00432-024-05728-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Soojung Hong Ju Hyun Lee Ja Yoon Heo Koung Jin Suh Se Hyun Kim Yu Jung Kim Jee Hyun Kim Source Type: research
Progressive changes in the protein expression profile of alveolar septa in early-stage lung adenocarcinoma
CONCLUSIONS: FAP-positive fibroblasts may contribute to tumor stroma formation in early-stage lung adenocarcinoma, and this could influence the development of therapeutic strategies targeting FAP-positive CAFs for disrupting extracellular matrix formation.PMID:38600426 | DOI:10.1007/s10147-024-02507-1 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Toru Kimura Takashi Akazawa Yu Mizote Harumi Nakamura Miki Sakaue Tomohiro Maniwa Yasushi Shintani Keiichiro Honma Hideaki Tahara Jiro Okami Source Type: research
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
CONCLUSIONS: All adverse effects were manageable and none resulted in patient death. In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer.PMID:38594880 | DOI:10.1093/jjco/hyae044 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Naoyuki Nogami Toshio Kubo Akihiro Bessho Makoto Sakugawa Satoshi Ikeo Toshihide Yokoyama Nobuhiko Seki Ryosuke Ochiai Nobukazu Fujimoto Shuji Murakami Kyoichi Kaira Toshiyuki Harada Daizo Kishino Yuichi Takiguchi Tsuneo Shimokawa Katsuyuki Kiura Natsumi Source Type: research
Emergency Department Visits Before Cancer Diagnosis Among Women at Mayo Clinic
CONCLUSION: Patient characteristics identified in this study offer opportunities to provide cancer risk assessment and health navigation, particularly among individuals with comorbidities and limited health care access.PMID:38596167 | PMC:PMC11002794 | DOI:10.1016/j.mayocpiqo.2024.03.002 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Sally K Stauder Shalmali R Borkar Amy E Glasgow Tage L Runkle Mark E Sherman Aaron C Spaulding Michael M Mohseni Christopher C DeStephano Source Type: research
Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC
CONCLUSIONS: The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.PMID:38596201 | PMC:PMC11001639 | DOI:10.1016/j.jtocrr.2024.100659 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Tsuyoshi Hirata Yuji Uehara Taiki Hakozaki Takayuki Kobayashi Yuto Terashima Kageaki Watanabe Makiko Yomota Yukio Hosomi Source Type: research
Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer
CONCLUSION: First-line ICIs plus chemotherapy should be applied in clinical practice. If patients did not use ICIs plus chemotherapy in first-line therapy, the use of ICIs in the second line or subsequent lines of treatment could prolong PFS2.PMID:38598001 | DOI:10.1007/s12094-024-03471-y (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Song Mi Yunxin Yang Xin Liu Shaotong Tang Ning Liang Jinyue Sun Chao Liu Qidong Ren Jihong Lu Pingping Hu Jiandong Zhang Source Type: research
Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography
CONCLUSION: Our nomogram based on preoperative 18F-FDG PET/CT radiological features and SUVmax effectively predicts STAS status in clinical-stage IA NSCLC. Furthermore, our study highlights that metabolic parameters and CT variables associated with STAS differ between solid and part-solid nodular NSCLC.PMID:38598007 | DOI:10.1007/s00432-024-05674-w (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Yun Wang Deng Lyu Chao Cheng Taohu Zhou Wenting Tu Yi Xiao Changjing Zuo Li Fan Shiyuan Liu Source Type: research
Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data
CONCLUSION: A high number of concurrent medications was associated with poor clinical outcomes.PMID:38600328 | DOI:10.1007/s00432-024-05728-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Soojung Hong Ju Hyun Lee Ja Yoon Heo Koung Jin Suh Se Hyun Kim Yu Jung Kim Jee Hyun Kim Source Type: research
Progressive changes in the protein expression profile of alveolar septa in early-stage lung adenocarcinoma
CONCLUSIONS: FAP-positive fibroblasts may contribute to tumor stroma formation in early-stage lung adenocarcinoma, and this could influence the development of therapeutic strategies targeting FAP-positive CAFs for disrupting extracellular matrix formation.PMID:38600426 | DOI:10.1007/s10147-024-02507-1 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Toru Kimura Takashi Akazawa Yu Mizote Harumi Nakamura Miki Sakaue Tomohiro Maniwa Yasushi Shintani Keiichiro Honma Hideaki Tahara Jiro Okami Source Type: research
Impact of proton PBS machine operating parameters on the effectiveness of layer rescanning for interplay effect mitigation in lung SBRT treatment
CONCLUSION: The effectiveness of layer rescanning for mitigating interplay effect is affected by machine operating parameters. Therefore, past clinical experiences may not be applicable to modern machines.PMID:38590112 | DOI:10.1002/acm2.14342 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Xiaoying Liang Chunbo Liu Jiajian Shen Stella Flampouri Justin C Park Bo Lu Sridhar Yaddanapudi Jun Tan Keith M Furutani Chris J Beltran Source Type: research
Stereotactic ablative radiotherapy for treating primary head and neck cancer and locoregional recurrence: A comprehensive review of the literature
CONCLUSIONS: SABR is an innovative, effective and promising treatment modality for small targets, especially in near proximity to organs at risk or in a pre-irradiated region. Prospective trials are further needed for this technique to become standard-of care.PMID:38590327 | PMC:PMC10999469 | DOI:10.1016/j.ctro.2024.100766 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Ciro Franzese Panagiotis Balermpas Source Type: research
